Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AXDIU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
IIIA4-USAN
|
|||||
| Synonyms |
Anti-EphA3 antibody-drug conjugate (Humanigen); Anti-EphA3 antibody-drug conjugate
Click to Show/Hide
|
|||||
| Organization |
Humanigen, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Glioblastoma [ICD11:2A00]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
2.81
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-EPHA3 mAb IIIA4
|
Antibody Info | ||||
| Antigen Name |
Ephrin type-A receptor 3 (EPHA3)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Emtansine
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.